Moderna says FDA delayed RSV vaccine approval to end of May
Publishing timestamp: 2024-05-10 07:00:01
Summary
Moderna's vaccine for respiratory syncytial virus approval by FDA delayed to end of May due to administrative constraints. Investors are closely watching as it would be the company's second product to launch in the U.S. after its Covid vaccine. Approval would showcase the versatility of Moderna's mRNA platform beyond treating Covid.
Sentiment: NEUTRAL
Tickers: PFE, GSK, GSK-GB, MRNA,
Keywords: health care industry, pfizer inc, fda, business, biotech and pharmaceuticals, biotechnology, breaking news, pharmaceuticals, moderna inc, business news, gsk plc,
Source: https://www.cnbc.com/2024/05/10/moderna-says-rsv-vaccine-fda-approval-delayed-to-end-of-may.html